European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 17 · Tue 6 Oct 

Molecules

Psilocybin

COMP360

5 assets8 European trial records0 deals

Chemical class
tryptamine alkaloid
Mechanism
Not independently verified.

Assets

European trials

Czechia 2

Denmark 3

France 2

Germany 2

Ireland 2

Italy 1

Netherlands 4

Poland 2

Spain 2

Sweden 4

Our calls

  • Issue 16OpenCompass discloses completion of its rolling NDA submission for COMP360, the FDA marketing application, on or before 31 December 2026.
  • Issue 13OpenNone of Slagelse DANP-RCT, Chieti psilocybin plus trazodone, or Amsterdam UMC adolescent PTSD has a ClinicalTrials.gov record by 31 December 2026. Falsifier: any one appears. Scored in the first January issue.
  • Issue 10OpenNo pharmaceutical company will be named as the responsible party on a BfArM compassionate use entry for psilocybin or MDMA before 31 December 2027. Our read, not anyone's stated plan.
  • Issue 9OpenCompass Pathways will NOT publicly disclose a marketing authorisation application to the MHRA or the EMA for COMP360 before 30 June 2027 — the end of its own guided US launch window. Our read, not Compass's stated plan; the company has said nothing about future European intent in either direction.
  • Issue 8OpenNo psilocybin or MDMA therapy will enter a formal health technology assessment or benefit assessment process in Germany, the Netherlands or the United Kingdom before 31 December 2027. Our read, not anyone's stated plan.
  • Issue 6OpenCOMP360 (Compass psilocybin) will NOT be commercially available to prescribe in the US by 30 June 2027 — i.e. the guided "first half of 2027" launch slips.

Record history